Systemic amyloidoses and proteomics: The state of the art

Francesca Lavatelli; Andrea di Fonzo; Giovanni Palladini; Giampaolo Merlini

doi:10.1016/j.euprot.2016.02.003

Systemic amyloidoses and proteomics: The state of the art

Francesca Lavatelli, Andrea di Fonzo, Giovanni Palladini, Giampaolo Merlini

IRCCS Fondazione Policlinico San Matteo

Research output: Contribution to journal › Article › peer-review

Abstract

Systemic amyloidoses are caused by misfolding-prone proteins that polymerize in tissues, causing organ dysfunction. Since proteins are etiological agents of these diseases, proteomics was soon recognized as a privileged instrument for their investigation. Mass spectrometry-based proteomics has acquired a fundamental role in management of systemic amyloidoses, being now considered a gold standard approach for amyloid typing. In parallel, approaches for analyzing circulating amyloid precursors have been developed. Moreover, differential and functional proteomics hold promise for identifying novel biomarkers and clarifying disease mechanisms. This review discusses recent proteomics achievements in systemic amyloidoses, providing a perspective on its present and future applications.

Original language	English
Pages (from-to)	4-10
Number of pages	7
Journal	EuPA Open Proteomics
Volume	11
DOIs	https://doi.org/10.1016/j.euprot.2016.02.003
Publication status	Published - Jun 1 2016

Keywords

Amyloidogenic proteins
Amyloidosis
Clinical proteomics
Proteotoxicity
Tissue biomarkers

ASJC Scopus subject areas

Biochemistry

Access to Document

10.1016/j.euprot.2016.02.003

Fingerprint Dive into the research topics of 'Systemic amyloidoses and proteomics: The state of the art'. Together they form a unique fingerprint.

Cite this

@article{2e81a334d026428190d0189a4107b5db,

title = "Systemic amyloidoses and proteomics: The state of the art",

abstract = "Systemic amyloidoses are caused by misfolding-prone proteins that polymerize in tissues, causing organ dysfunction. Since proteins are etiological agents of these diseases, proteomics was soon recognized as a privileged instrument for their investigation. Mass spectrometry-based proteomics has acquired a fundamental role in management of systemic amyloidoses, being now considered a gold standard approach for amyloid typing. In parallel, approaches for analyzing circulating amyloid precursors have been developed. Moreover, differential and functional proteomics hold promise for identifying novel biomarkers and clarifying disease mechanisms. This review discusses recent proteomics achievements in systemic amyloidoses, providing a perspective on its present and future applications.",

keywords = "Amyloidogenic proteins, Amyloidosis, Clinical proteomics, Proteotoxicity, Tissue biomarkers",

author = "Francesca Lavatelli and {di Fonzo}, Andrea and Giovanni Palladini and Giampaolo Merlini",

year = "2016",

month = jun,

day = "1",

doi = "10.1016/j.euprot.2016.02.003",

language = "English",

volume = "11",

pages = "4--10",

journal = "EuPA Open Proteomics",

issn = "2212-9685",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Systemic amyloidoses and proteomics

T2 - The state of the art

AU - Lavatelli, Francesca

AU - di Fonzo, Andrea

AU - Palladini, Giovanni

AU - Merlini, Giampaolo

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Systemic amyloidoses are caused by misfolding-prone proteins that polymerize in tissues, causing organ dysfunction. Since proteins are etiological agents of these diseases, proteomics was soon recognized as a privileged instrument for their investigation. Mass spectrometry-based proteomics has acquired a fundamental role in management of systemic amyloidoses, being now considered a gold standard approach for amyloid typing. In parallel, approaches for analyzing circulating amyloid precursors have been developed. Moreover, differential and functional proteomics hold promise for identifying novel biomarkers and clarifying disease mechanisms. This review discusses recent proteomics achievements in systemic amyloidoses, providing a perspective on its present and future applications.

AB - Systemic amyloidoses are caused by misfolding-prone proteins that polymerize in tissues, causing organ dysfunction. Since proteins are etiological agents of these diseases, proteomics was soon recognized as a privileged instrument for their investigation. Mass spectrometry-based proteomics has acquired a fundamental role in management of systemic amyloidoses, being now considered a gold standard approach for amyloid typing. In parallel, approaches for analyzing circulating amyloid precursors have been developed. Moreover, differential and functional proteomics hold promise for identifying novel biomarkers and clarifying disease mechanisms. This review discusses recent proteomics achievements in systemic amyloidoses, providing a perspective on its present and future applications.

KW - Amyloidogenic proteins

KW - Amyloidosis

KW - Clinical proteomics

KW - Proteotoxicity

KW - Tissue biomarkers

UR - http://www.scopus.com/inward/record.url?scp=84959345894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959345894&partnerID=8YFLogxK

U2 - 10.1016/j.euprot.2016.02.003

DO - 10.1016/j.euprot.2016.02.003

M3 - Article

AN - SCOPUS:84959345894

VL - 11

SP - 4

EP - 10

JO - EuPA Open Proteomics

JF - EuPA Open Proteomics

SN - 2212-9685

ER -